Cite
HARVARD Citation
Lorenzen, S. et al. (2020). Phase III randomized, double‐blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum‐containing regimen (RADPAC). International journal of cancer. 147 (9), pp. 2493-2502. [Online].